The status of pharmacometrics in pregnancy: Highlights from the 3rd American conference on pharmacometrics

British Journal of Clinical Pharmacology

Volumn 74, Issue 6, 2012, Pages 932-939

  van Hasselt, J G Coen ^a   Andrew, Marilee A ^b   Hebert, Mary F ^c   Tarning, Joel ^d   Vicini, Paolo ^e   Mattison, Donald R ^f,g  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b AMGEN INC   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d MAHIDOL UNIVERSITY   (Thailand)

^e PFIZER INC   (United States)

^f EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^g RISK SCIENCES INTERNATIONAL   (Canada)

Author keywords

Maternal fetal medicine; Modelling and simulation; Pharmacokinetics; Pharmacometrics; Pregnancy

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; ANTIMALARIAL AGENT; ARTEMETHER; ARTEMETHER PLUS BENFLUMETOL; ARTESUNATE; ATOVAQUONE; BENFLUMETOL; CYCLOGUANIL; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A; DIHYDROARTEMISININ; GLIBENCLAMIDE; OSELTAMIVIR; PROGUANIL; PYRIMETHAMINE; SULFADOXINE;

ANTHRAX; ANTIBIOTIC PROPHYLAXIS; AREA UNDER THE CURVE; ARTICLE; BACILLUS ANTHRACIS; COMPUTER MODEL; COMPUTER PREDICTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG TREATMENT FAILURE; FEMALE; FETOPLACENTAL UNIT; GLOMERULUS FILTRATION RATE; HUMAN; INFLUENZA; MALARIA; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MEDICAL ETHICS; MINIMUM INHIBITORY CONCENTRATION; MODEL; OPTIMAL DRUG DOSE; PHARMACOLOGICAL SCIENCE; PHARMACOMETRICS; PHYSIOLOGICAL PROCESS; PLASMODIUM FALCIPARUM; PREGNANCY; PREGNANCY DIABETES MELLITUS; PREGNANT WOMAN; PRIORITY JOURNAL; PROCESS OPTIMIZATION; RECOMMENDED DRUG DOSE; SECOND TRIMESTER PREGNANCY; THIRD TRIMESTER PREGNANCY; TIME TO MAXIMUM PLASMA CONCENTRATION;

BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; FEMALE; HUMANS; MATERNAL-FETAL EXCHANGE; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PHARMACOLOGY; PREGNANCY; RESEARCH DESIGN;

EID: 84869058991     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2012.04280.x     Document Type: Article

References (56)

1. Andrade SE, Gurwitz JH, Davis RL, Chan KA, Finkelstein JA, Fortman K, McPhillips H, Raebel MA, Roblin D, Smith DH, Yood MU, Morse AN, Platt R. Prescription drug use in pregnancy. Am J Obstet Gynecol 2004; 191: 398-407.
2. Saunders EJ, Saunders JA. Drug therapy in pregnancy: the lessons of diethylstilbestrol, thalidomide, and bendectin. Health Care Women Int 1990; 11: 423-32.
3. McCullough LB, Coverdale JH, Chervenak FA. A comprehensive ethical framework for responsibly designing and conducting pharmacologic research that involves pregnant women. Am J Obstet Gynecol 2005; 193: 901-7.
4. Anderson GD. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin Pharmacokinet 2005; 44: 989-1008.
5. Feghali MN, Mattison DR. Clinical therapeutics in pregnancy. J Biomed Biotechnol 2011; 2011: 783528.
6. Gillespie WR. Noncompartmental versus compartmental modelling in clinical pharmacokinetics. Clin Pharmacokinet 1991; 20: 253-62.
7. DiStefano JJ. Noncompartmental vs. compartmental analysis: some bases for choice. Am J Physiol 1982; 243: R1-6.
8. Jang GR, Harris RZ, Lau DT. Pharmacokinetics and its role in small molecule drug discovery research. Med Res Rev 2001; 21: 382-96.
9. Sheiner L, Wakefield J. Population modelling in drug development. Stat Methods Med Res 1999; 8: 183-93.
10. Corley RA, Mast TJ, Carney EW, Rogers JM, Daston GP. Evaluation of physiologically based models of pregnancy and lactation for their application in children's health risk assessments. Crit Rev Toxicol 2003; 33: 137-211.
11. Andrew MA, Hebert MF, Vicini P. Physiologically based pharmacokinetic model of midazolam disposition during pregnancy. Annual International Conf Proc IEEE Eng Med Biol Soc 2008; 2008: 5454-7.
12. Gaohua L, Abduljalil K, Furness P, Jamei M, Rostami-Hodjegan A, Soltani H. A Time-Varying Physiologically-Based Pharmacokinetic Model of Caffeine during Pregnancy. The John Rylands University Library, The University of Manchester, Manchester, 2010.
13. Andrew M, Hebert M, Vicini P. Physiologically based pharmacokinetic (PBPK) modeling of midazolam disposition in pregnant and postpartum women. Abstracts of the Annual Meeting of the PAGE 2010; 19: 1760.
14. Holford N, Ma SC, Ploeger BA. Clinical trial simulation: a review. Clin Pharmacol Ther 2010; 88: 166-82.
15. Duffull SB. Design of clinical pharmacology trials. Clin Exp Pharmacol Physiol 2001; 28: 905-12.
16. Naritomi Y, Terashita S, Kagayama A. Identification and relative contributions of human cytochrome P450 isoforms involved in the metabolism of glibenclamide and lansoprazole: evaluation of an approach based on the in vitro substrate disappearance rate. Xenobiotica 2004; 34: 415-27.
17. van Giersbergen PLM, Treiber A, Clozel M, Bodin F, Dingemanse J. In vivo and in vitro studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburide. Clin Pharmacol Ther 2002; 71: 253-62.
18. Hebert MF, Easterling TR, Kirby B, Carr DB, Buchanan ML, Rutherford T, Thummel KE, Fishbein DP, Unadkat JD. Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: a University of Washington specialized center of research study. Clin Pharmacol Ther 2008; 84: 248-53.
19. Yerby MS, Friel PN, McCormick K, Koerner M, Van Allen M, Leavitt AM, Sells CJ, Yerby JA. Pharmacokinetics of anticonvulsants in pregnancy: alterations in plasma protein binding. Epilepsy Res 1990; 5: 223-8.
20. McGready R, Stepniewska K, Seaton E, Cho T, Cho D, Ginsberg A, Edstein MD, Ashley E, Looareesuwan S, White NJ, Nosten F. Pregnancy and use of oral contraceptives reduces the biotransformation of proguanil to cycloguanil. Eur J Clin Pharmacol 2003; 59: 553-7.
21. Hebert MF, Ma X, Naraharisetti SB, Krudys KM, Umans JG, Hankins GDV, Caritis SN, Miodovnik M, Mattison DR, Unadkat JD, Kelly EJ, Blough D, Cobelli C, Ahmed MS, Snodgrass WR, Carr DB, Easterling TR, Vicini P. Are we optimizing gestational diabetes treatment with glyburide? The pharmacologic basis for better clinical practice. Clin Pharmacol Ther 2009; 85: 607-14.
22. American College of Obstetricians and Gynecologists. Management of asymptomatic pregnant or lactating women exposed to anthrax. Obstet Gynecol 2002; 99: 366-8.
23. Gordon C, Regamey C, Kirby WM. Comparative clinical pharmacology of amoxicillin and ampicillin administered orally. Antimicrob Agents Chemother 1972; 1: 504-7.
24. Croydon EA, Sutherland R. Amino-p-hydroxybenzylpenicillin (BRL 2333), a new semisynthetic penicillin: absorption and excretion in man. Antimicrob Agents Chemother 1970; 10: 427-30.
25. Sjövall J, Alván G, Westerlund D. Dose-dependent absorption of amoxycillin and bacampicillin. Clin Pharmacol Ther 1985; 38: 241-50.
26. Davison JM, Dunlop WEM. 24-hour creatinine clearance during the third trimester of normal pregnancy. Br J Obstet Gynaecol 1989; 87: 106-9.
27. Davison JM, Noble MCB. Serial changes in 24 hour creatinine clearance during normal menstrual cycles and the first trimester of pregnancy. Br J Obstet Gynaecol 1981; 88: 10-7.
28. Andrew MA, Easterling TR, Carr DB, Shen D, Buchanan ML, Rutherford T, Bennett R, Vicini P, Hebert MF. Amoxicillin pharmacokinetics in pregnant women: modeling and simulations of dosage strategies. Clin Pharmacol Ther 2007; 81: 547-56.
29. Dellicour S, Tatem A, Guerra C, Snow R, ter Kuile F. Quantifying the number of pregnancies at risk of malaria in 2007: a demographic study. PLoS Med 2010; 7: e1000221.
30. McGready R, Stepniewska K, Ward SA, Cho T, Gilveray G, Looareesuwan S, White NJ, Nosten F. Pharmacokinetics of dihydroartemisinin following oral artesunate treatment of pregnant women with acute uncomplicated falciparum malaria. Eur J Clin Pharmacol 2006; 62: 367-71.
31. McGready R, Stepniewska K, Lindegardh N, Ashley EA, La Y, Singhasivanon P, White NJ, Nosten F. The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria. Eur J Clin Pharmacol 2006; 62: 1021-31.
32. Karunajeewa HA, Salman S, Mueller I, Baiwog F, Gomorrai S, Law I, Page-Sharp M, Rogerson S, Siba P, Ilett KF, Davis TME. Pharmacokinetic properties of sulfadoxine-pyrimethamine in pregnant women. Antimicrob Agents Chemother 2009; 53: 4368-76.
33. Tarning J, McGready R, Lindegardh N, Ashley EA, Pimanpanarak M, Kamanikom B, Annerberg A, Day NPJ, Stepniewska K, Singhasivanon P, White NJ, Nosten F. Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria. Antimicrob Agents Chemother 2009; 53: 3837-46.
34. Nyunt MM, Adam I, Kayentao K, van Dijk J, Thuma P, Mauff K, Little F, Cassam Y, Guirou E, Traore B, Doumbo O, Sullivan D, Smith P, Barnes KI. Pharmacokinetics of sulfadoxine and pyrimethamine in intermittent preventive treatment of malaria in pregnancy. Clin Pharmacol Ther 2010; 87: 226-34.
35. McGready R, White NJ, Nosten F. Parasitological efficacy of antimalarials in the treatment and prevention of falciparum malaria in pregnancy 1998 to 2009: a systematic review. BJOG 2011; 118: 123-35.
36. Jamsen KM, Duffull SB, Tarning J, Lindegardh N, White NJ, Simpson JA. Optimal designs for population pharmacokinetic studies of oral artesunate in patients with uncomplicated falciparum malaria. Malar J 2011; 10: 181.
37. Mosby LG, Rasmussen SA, Jamieson DJ. 2009 Pandemic influenza A (H1N1) in pregnancy: a systematic review of the literature. Am J Obstet Gynecol 2011; 205: 10-8.
38. Morrison D, Roy S, Rayner C, Amer A, Howard D, Smith JR, Evans TG. A randomized, crossover study to evaluate the pharmacokinetics of amantadine and oseltamivir administered alone and in combination. PLoS ONE 2007; 2: e1305.
39. Wattanagoon Y, Stepniewska K, Lindegårdh N, Pukrittayakamee S, Silachamroon U, Piyaphanee W, Singtoroj T, Hanpithakpong W, Davies G, Tarning J, Pongtavornpinyo W, Fukuda C, Singhasivanon P, Day NPJ, White NJ. Pharmacokinetics of high-dose oseltamivir in healthy volunteers. Antimicrob Agents Chemother 2009; 53: 945-52.
40. Rayner CR, Chanu P, Gieschke R, Boak LM, Jonsson EN. Population pharmacokinetics of oseltamivir when coadministered with probenecid. J Clin Pharmacol 2008; 48: 935-47.
41. Jhee SS, Yen M, Ereshefsky L, Leibowitz M, Schulte M, Kaeser B, Boak L, Patel A, Hoffmann G, Prinssen EP, Rayner CR. Low penetration of oseltamivir and its carboxylate into cerebrospinal fluid in healthy Japanese and Caucasian volunteers. Antimicrob Agents Chemother 2008; 52: 3687-93.
42. Snell P, Dave N, Wilson K, Rowell L, Weil A, Galitz L, Robson R. Lack of effect of moderate hepatic impairment on the pharmacokinetics of oral oseltamivir and its metabolite oseltamivir carboxylate. Br J Clin Pharmacol 2005; 59: 598-601.
43. Hill G, Cihlar T, Oo C, Ho ES, Prior K, Wiltshire H, Barrett J, Liu B, Ward P. The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies. Drug Metab Dispos 2002; 30: 13-9.
44. Oo C, Hill G, Dorr A, Liu B, Boellner S, Ward P. Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1 5 years. Eur J Clin Pharmacol 2003; 59: 411-5.
45. Robson R, Buttimore A, Lynn K, Brewster M, Ward P. The pharmacokinetics and tolerability of oseltamivir suspension in patients on haemodialysis and continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 2006; 21: 2556-62.
46. Massarella JW, He GZ, Dorr A, Nieforth K, Ward P, Brown A. The pharmacokinetics and tolerability of the oral neuraminidase inhibitor oseltamivir (Ro 64-0796/GS4104) in healthy adult and elderly volunteers. J Clin Pharmacol 2000; 40: 836-43.
47. Snell P, Oo C, Dorr A, Barrett J. Lack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacids. Br J Clin Pharmacol 2002; 54: 372-7.
48. Oo C, Barrett J, Dorr A, Liu B, Ward P. Lack of pharmacokinetic interaction between the oral anti-influenza prodrug oseltamivir and aspirin. Antimicrob Agents Chemother 2002; 46: 1993-5.
49. Schentag JJ, Hill G, Chu T, Rayner CR. Similarity in pharmacokinetics of oseltamivir and oseltamivir carboxylate in Japanese and Caucasian subjects. J Clin Pharmacol 2007; 47: 689-96.
50. Holodniy M, Penzak SR, Straight TM, Davey RT, Lee KK, Goetz MB, Raisch DW, Cunningham F, Lin ET, Olivo N, Deyton LR. Pharmacokinetics and tolerability of oseltamivir combined with probenecid. Antimicrob Agents Chemother 2008; 52: 3013-21.
51. Brewster M, Smith JR, Dutkowski R, Robson R. Active metabolite from Tamiflu solution is bioequivalent to that from capsule delivery in healthy volunteers: a cross-over, randomised, open-label study. Vaccine 2006; 24: 6660-3.
52. Abe M, Smith J, Urae A, Barrett J, Kinoshita H, Rayner CR. Pharmacokinetics of oseltamivir in young and very elderly subjects. Ann Pharmacother 2006; 40: 1724-30.
53. Greer LG, Leff RD, Rogers VL, Roberts SW, McCracken GH, Wendel GD, Sheffield JS. Pharmacokinetics of oseltamivir according to trimester of pregnancy. Am J Obstet Gynecol 2011; 204: (Suppl. 1): S89-93.
54. Beigi RH, Han K, Venkataramanan R, Hankins GD, Clark S, Hebert MF, Easterling T, Zajicek A, Ren Z, Mattison DR, Caritis SN. Pharmacokinetics of oseltamivir among pregnant and nonpregnant women. Am J Obstet Gynecol 2011; 204: (Suppl. 1): S84-8.
55. Mirochnick M, Clarke D. Oseltamivir pharmacokinetics in pregnancy: a commentary. Am J Obstet Gynecol 2011; 204: (Suppl. 1): S94-5.
56. van Hasselt JGC, Green B, Morrish GM. Leveraging physiological data from the literature into a pharmacokinetic model to support informative clinical study design in pregnant women. Pharm Res 2012; DOI: 10.1007/s11095-012-0671-2. [Epub ahead of print].